Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 8;7(15):3842-3845.
doi: 10.1182/bloodadvances.2023009714.

Teclistamab impairs detection of BCMA CAR-T cells

Bettina Glatte  1 , Kerstin Wenk  1 , Anja Grahnert  1   2 , Maik Friedrich  1 , Maximilian Merz  3 , Vladan Vucinic  3 , Luise Fischer  3 , Kristin Reiche  1   2 , Miriam Alb  4 , Michael Hudecek  4 , Paul Franz  2 , Stephan Fricke  2 , Uwe Platzbecker  3 , Ulrike Koehl  1   2   5 , Ulrich Sack  1 , Andreas Boldt  1 , Sunna Hauschildt  1   6 , Ronald Weiss  1   2
Affiliations

Teclistamab impairs detection of BCMA CAR-T cells

Bettina Glatte et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.M., V.V., and U.P. receive honoraria from Janssen and BMS. M.M. is also supported by Janssen Research. S.F. was a consultant for Janssen-Cilag. S.F., P.F., R.W., and A.G. are involved, in collaborations with Novartis and Miltenyi Biotec, in the production of CAR-T cells. M.H. receive speaker honoraria from Novartis, Janssen, Celgene/BMS, and has participated in scientific advisory boards for Janssen and Celgene/BMS. M.H. is listed as an inventor of patent applications and granted patents related to CAR technologies and CAR T-cell therapy that have been filed by the Fred Hutchinson Cancer Research Center and the University of Wuerzburg, and that have been, in part, licensed to industry. M.H. is the cofounder and equity owner of T-CURX GmbH, Wuerzburg, Germany. U.K. is a consultant in immune-oncology for AstraZeneca, Affimed, Glycostem, GammaDelta, and Zelluna and has collaborations with Novartis and Miltenyi Biotec regarding the production of CAR-T cells. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Interference of BCMA CAR-T cell detection with teclistamab. (A) Schematic overview of BCMA CAR-T cell detection. (B-D) BCMA CAR-T cell detection by flow cytometry of 5 samples of patients with MM (B) at the time of leukapheresis and (C) 12 to 14 days after BCMA CAR-T cell treatment (Ide-cel). Furthermore, samples from 5 patients pretreated with teclistamab were analyzed (D) at the time of leukapheresis. Dashed lines indicate cutoff values for defining CAR-positive T cells. (E) (Top) schematic overview of BCMA CAR DNA, including the location of forward (fwd) and reverse (rev) primers. (E) (Bottom) gel electrophoresis of quantitative PCR amplified BCMA CAR DNA products from samples of patients with MM, taken at the time of leukapheresis (LP); 14 days after CAR-T cell administration (Ide-cel) (14 days) and at leukapheresis with teclistamab pretreatment (LP + tec.). Human Growth Hormone 1 (hGH1) served as the reference gene and aqua dest. (a.d.) as the negative control. Shown is 1 experiment out of 5. The gel image was adjusted for contrast and brightness, with no nonlinear adjustments. (F) Schematic overview of the recognition of teclistamab binding to CD3 T cells using BCMA CAR detection reagent. TM, transmembrane domain.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Xiao X, Wang Y, Zou Z, et al. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies. Front Immunol. 2022;13 - PMC - PubMed
    1. Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385(9983):2197–2208. - PubMed
    1. Reichman A, Kunz A, Joedicke JJ, et al. Comparison of FACS and PCR for detection of BCMA-CAR-T cells. Int J Mol Sci. 2022;23(2):903. - PMC - PubMed
    1. Tang Y, Yin H, Zhao X, et al. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. J Exp Clin Cancer Res. 2022;41(1):2. - PMC - PubMed
    1. Strassl I, Schreder M, Steiner N, et al. The agony of choice-where to place the wave of BCMA-targeted therapies in the multiple myeloma treatment puzzle in 2022 and beyond. Cancers (Basel) 2021;13(18):4701. - PMC - PubMed

MeSH terms

Substances